RxDoctor Payments Data

Chima Nwizu, MD

Family Medicine · Greeley, CONPI 1902882517

Payments from drug & device makers

$5,280in general payments, 2019–2025

Across 208 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$844
  • Amgen$550
  • AbbVie$462
  • Sanofi-aventis U.S. LLC$432
  • Lilly USA, LLC$394
  • Bayer$243
  • plus $2K from 37 others

What the payments were for

  • Consulting fees$5009%
  • Food & beverage$4,69089%
  • Education$912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,280 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$21,909
Medicare patients
29
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$57,872
OzempicSemaglutide23$32,873
KerendiaFinerenone19$28,541
JardianceEmpagliflozin11$17,062
VascepaIcosapent Ethyl15$9,136
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,925
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$1,871
Ezetimibe69$1,670
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,622
Novolog FlexpenInsulin Aspart12$1,424
Ursodiol13$1,419
Carbidopa-Levodopa ErCarbidopa/Levodopa13$1,379
Fentanyl11$1,259
Atorvastatin Calcium131$1,073
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$394$57,87254 claims
Novo NordiskOzempic$188$32,87323 claims
BayerKerendia$243$28,54119 claims
Boehringer IngelheimJardiance$67$17,06211 claims
GSKTrelegy Ellipta$236$6,92511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Greeley

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →